Vaxcyte (PCVX) Net Equity Issued and Repurchased (2020 - 2025)
Vaxcyte (PCVX) posted quarterly Net Equity Issued and Repurchased of $264.2 million for Q1 2025, up 1016253.85% quarter-over-quarter from -$26000.0 in Q4 2024.
Vaxcyte (PCVX) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
Vaxcyte (PCVX) has reported Net Equity Issued and Repurchased for 6 consecutive years, with $264.2 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $264.2 million; the TTM figure through Dec 2025 stood at $264.2 million (up 34.84% YoY), while the FY2025 annual figure was $264.2 million, up 34.84% from the prior year.
- Net Equity Issued and Repurchased climbed to $264.2 million in Q1 2025 per PCVX's latest filing, from -$26000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $264.2 million in Q1 2025 and bottomed at -$46000.0 in Q4 2023.
- Historically, Net Equity Issued and Repurchased has averaged $50.9 million across 5 years, with a median of $41.8 million in 2023.
- On a YoY basis, Net Equity Issued and Repurchased climbed as much as 1241.48% in 2023 and fell as far as 102.23% in 2023.
- Vaxcyte's Net Equity Issued and Repurchased stood at $6.8 million in 2021, then slumped by 69.64% to $2.1 million in 2022, then plunged by 102.23% to -$46000.0 in 2023, then soared by 43.48% to -$26000.0 in 2024, then jumped by 1016253.85% to $264.2 million in 2025.
- Business Quant data shows PCVX's Net Equity Issued and Repurchased at $264.2 million in Q1 2025, -$26000.0 in Q4 2024, and $89.5 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 264.20 Mn |
| Mar 31, 2025 | 264.20 Mn |
| Dec 31, 2024 | -26,000.00 |
| Dec 31, 2024 | -26,000.00 |
| Sep 30, 2024 | 89.46 Mn |
| Sep 30, 2024 | 89.46 Mn |
| Jun 30, 2024 | 106.51 Mn |
| Jun 30, 2024 | 106.51 Mn |
| Dec 31, 2023 | -46,000.00 |
| Dec 31, 2023 | -46,000.00 |
| Sep 30, 2023 | 49.00 Mn |
| Sep 30, 2023 | 49.00 Mn |
| Mar 31, 2023 | 41.79 Mn |
| Mar 31, 2023 | 41.79 Mn |
| Dec 31, 2022 | 2.06 Mn |
| Dec 31, 2022 | 2.06 Mn |
| Sep 30, 2022 | 43.12 Mn |
| Sep 30, 2022 | 43.12 Mn |
| Jun 30, 2022 | 49.00 Mn |
| Jun 30, 2022 | 49.00 Mn |